|
|
Article: Cobalis Locks Database for Pivotal Twin Phase III Trials of PreHistin(TM) in Seasonal Allergic Rhinitis.
- Article from:
- Business Wire
- Article date:
- March 29, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IRVINE, Calif. -- Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, today announced that it has completed the locking of the database for its pivotal twin Phase III Clinical Trials of PreHistin[TM] in seasonal allergic rhinitis. An independent contract research organization (CRO) will now begin the process of implementing the statistical analysis plan designed to analyze the data from the pivotal trials.
"We are pleased to have reached this milestone in our PreHistin trials and look forward to reporting top-line results over the next month," commented Dr. Gerald J. Yakatan, Chief Executive Officer for ...